5 October 2021 - On 1 October 2021, the TGA granted provisional determination to Pfizer in relation to a new combination medicine containing PF-07321332 and ritonavir, for the treatment of adult patients with symptomatic, confirmed coronavirus infection.

PF-07321332 is an oral antiviral treatment. It is intended to be administered in combination with low-dose ritonavir - to maintain plasma levels of PF-07321332 for the duration of the treatment.

Read TGA News